What is Abcuro?
Abcuro operates at the vanguard of the biotechnology sector, specializing in the development of first-in-class immunotherapies. The company's core competency lies in the precise modulation of highly cytotoxic T cells, a mechanism designed to address significant unmet needs in autoimmune diseases and cancer. Its lead candidate, ulviprubart (ABC008), is currently undergoing rigorous clinical evaluation for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia. By focusing on targeted cellular intervention, Abcuro distinguishes itself from traditional broad-spectrum immunosuppressive therapies, offering a more refined approach to disease management.
How much funding has Abcuro raised?
Abcuro has raised a total of $473.3M across 3 funding rounds:
Series A
$50M
Series B
$155M
Series C
$200M
Series A (2021): $50M with participation from Hongsen Investment Group, Pontifax, Mass General Brigham Ventures, Sanofi Ventures, Samsara BioCapital, and RA Capital Management
Series B (2023): $155M led by RA Capital Management, Redmile Group, Samsara BioCapital, and Sanofi Ventures
Series C (2025): $200M supported by BlackRock, Mass General Brigham Ventures, Pontifax, Soleus Capital, Samsara BioCapital, New Enterprise Associates, Eurofarma, Bain Capital, Foresite Capital, Redmile Group, RA Capital Management, and Sanofi Ventures
Key Investors in Abcuro
BlackRock
BlackRock is a global investment management firm providing comprehensive financial services and alternative investments to institutional and individual clients worldwide.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing its internal TechAtlas think tank to support scientific and clinical strategy.
Pontifax
Pontifax Venture Capital specializes in groundbreaking innovations in life sciences, providing hands-on guidance and strategic direction to clinical-stage companies across the healthcare spectrum.
What's next for Abcuro?
With the infusion of this latest capital, Abcuro is set to scale its clinical operations and expand its research infrastructure. The strategic focus will remain on the successful execution of ongoing clinical trials for ulviprubart, with an eye toward potential regulatory milestones and future commercialization pathways. As the company matures, the emphasis will likely shift toward optimizing its therapeutic platform and exploring additional indications where T cell modulation can provide superior patient outcomes. This funding provides the necessary runway to sustain long-term R&D efforts while maintaining a competitive edge in the rapidly evolving landscape of precision medicine.
See full Abcuro company page
